Evoke Pharma, Inc. (EVOK) Releases Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Evoke Pharma, Inc. (NASDAQ:EVOK) issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.13), Bloomberg Earnings reports. During the same quarter last year, the company posted ($0.29) EPS.

Shares of Evoke Pharma (NASDAQ:EVOK) traded down $0.15 during trading hours on Wednesday, hitting $2.69. The stock had a trading volume of 228,046 shares, compared to its average volume of 428,354. Evoke Pharma has a 1 year low of $1.42 and a 1 year high of $4.55.

An institutional investor recently raised its position in Evoke Pharma stock. Vanguard Group Inc. increased its holdings in Evoke Pharma, Inc. (NASDAQ:EVOK) by 15.1% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 523,650 shares of the specialty pharmaceutical company’s stock after buying an additional 68,544 shares during the quarter. Vanguard Group Inc. owned about 3.40% of Evoke Pharma worth $1,341,000 at the end of the most recent reporting period. 12.87% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Evoke Pharma, Inc. (EVOK) Releases Quarterly Earnings Results, Misses Expectations By $0.13 EPS” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.themarketsdaily.com/2017/11/15/evoke-pharma-inc-evok-releases-quarterly-earnings-results-misses-expectations-by-0-13-eps.html.

A number of brokerages have commented on EVOK. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Evoke Pharma in a research report on Tuesday, August 15th. Zacks Investment Research lowered Evoke Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. ValuEngine raised Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Northland Securities reissued a “buy” rating and set a $10.00 price objective on shares of Evoke Pharma in a research note on Wednesday, October 18th. Finally, FBR & Co reaffirmed a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a research note on Thursday, October 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $8.86.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Earnings History for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply